Explore ›
Finding
Finding
improvement
In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associated with a 31% lower cardiovascular event rate compared with simvastatin alone (interaction p=0.057).
| Effect size | 31% lower event rate |
| Follow-up | 4.7 years |
| Comparator | Placebo added to simvastatin (20-40 mg/day) |
| Effect summary | improvement; 31% lower event rate |
Connected entities
Interventions
Conditions
Populations
Source
PMC4509601
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus